In recent years, the isolation rate of carbapenem-resistant Klebsiella pneumoniae (CRKP) in China has increased year by year. Due to its multidrug resistance and high mortality in patients, CRKP brings severe challenges to the clinical treatment. The major mechanism of drug resistance in CRKP is the production of carbapenemases, with Ambler A, B, and D being the common types while Ambler type C comparativly rare. Klebsiella pneumoniae carbapenemase (KPC) is the most common carbapenemase, which belongs to type A. KPC-producing Klebsiella pneumoniae (KPC-KP) widely spreads in the world, with very limited number of effective clinical drugs. In this review, advances in the treatment KPC-KP were summarized to provide reference for clinical treatment.